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Introduction: Targeted biologic therapies demonstrate similar efficacies in rheumatoid arthritis despite distinct mechanisms of
action. They also exhibit a ceiling effect, with 10% to 20% of patients achieving remission in clinical trials. None of these therapies
target synovial fibroblasts, which drive and maintain synovitis. Seliciclib (R-roscovitine) is an orally available cyclin-dependent kinase
inhibitor that suppresses fibroblast proliferation, and is efficacious in preclinical arthritis models. We aim to determine the toxicity and
preliminary efficacy of seliciclib in combination with biologic therapies, to inform its potential as an adjunctive therapy in rheumatoid
arthritis.
Methods and analysis: TRAFIC is a non-commercial, multi-center, rolling phase Ib/IIa trial investigating the safety, tolerability,
and efficacy of seliciclib in patients with moderate to severe rheumatoid arthritis receiving biologic therapies. All participants receive
seliciclib with no control arm. The primary objective of part 1 (phase Ib) is to determine the maximum tolerated dose and safety of
seliciclib over 4 weeks of dosing. Part 1 uses a restricted 1-stage Bayesian continual reassessment method based on a target dose-
limiting toxicity probability of 35%. Part 2 (phase IIa) assesses the potential efficacy of seliciclib, and is designed as a single arm, single
stage early phase trial based on a Fleming-A’Hern design using the maximum tolerated dose recommended from part 1. The primary
response outcome after 12 weeks of therapy is a composite of clinical, histological and magnetic resonance imaging scores.
Secondary outcomes include adverse events, pharmacodynamic and pharmacokinetic parameters, autoantibodies, and fatigue.
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rheumatoid arthritis, seliciclib1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory arthritis
characterized by joint pain, swelling, and damage.[1] RA is a
major global public health challenge, with an estimated global
prevalence of almost 20 million and significant impact on
disability adjusted life years.[2] Around a third of people with RA
have stopped working within 2 years of onset and around a half
by 10 years, with significant costs to the economy in sick leave
and work-related disability.[3] Suboptimally controlled joint
inflammation in RA leads to damage, deformity, disability, and
impaired quality of life. Chronic inflammation reduces life
expectancy by increasing the risk of cardiovascular disease.
Advances in RA management strategies and targeted biologic
therapies have contributed to significantly improved prognosis
and outcomes for people with RA. However, there remains
significant unmet clinical need. There is no cure for RA and, even
with the best available therapies, only 20% to 30% of patients
achieve remission, while 5% to 10% are refractory to all current
treatments.[4]
Despite modulating different implicated immune pathways,
current targeted therapies exhibit remarkably similar response
rates in clinical trials. On average, 50% to 60% of participants
improve by 20% (American College of Rheumatology (ACR) 20
response), 30% to 40% improve by 50% (ACR50) and 10% to
20% improve by 70% (ACR70). As current therapies target
primary immune cells and cytokines, an untested hypothesis is
that RA synovial fibroblasts may themselves drive and maintain
synovitis, explaining the apparent “ceiling effect” of current
therapies, which do not target these cells. RA synovial fluid also
contains abundant neutrophils,[5] which secrete pro-inflammato-
ry mediators and tissue-destructive enzymes not specifically
targeted by current therapies. A therapy that addresses the
abnormal behaviour of RA synovial fibroblasts, particularly with
potential additional actions on monocytes/macrophages and
neutrophils,[6,7] could have a unique niche in RA management.
Cell proliferation is dependent on orderly progression through
the cell cycle, which is regulated by tightly controlled formation
and activation of complexes comprising cyclin proteins and
cyclin-dependent kinases (CDKs). Dysregulation of cyclin-CDK
pathways has been demonstrated in many tumors, and their
manipulation consequently exploited to develop anti-cancer
drugs.[8] However altered cytokine and tissue destructive
enzymes due to dysregulation of these pathways has also been
reported in RA synovial fibroblasts.[9–11] Seliciclib (R-roscovi-
tine) is an orally available cyclin dependent kinase inhibitor that
selectively targets CDK2, CDK7, and CDK9.[12,13] In addition to2directly suppressing fibroblast proliferation by inhibiting CDK2,
seliciclib induces p21,[14,9] an endogenous CDK inhibitor whose
activity is down-regulated in RA synovial fibroblasts.[10,15]
Furthermore, inhibition of CDK7 and CDK9 reduces transcrip-
tion of MCL1, which reduces viability of synovial fibroblasts,
neutrophils, and macrophages.[16] In vitro seliciclib causes
growth inhibition and apoptosis of abnormally dividing cells,
leaving normally dividing cells unaffected.[17–20] Seliciclib and
related CDKIs have demonstrated good efficacy and potency in
preclinical models of arthritis.[21–25] Additionally, genetic studies
have implicated CDK inhibition as a plausible therapeutic
strategy in RA, and support investigation of CDK inhibition in
RA.[26] Specific interactions of conventional synthetic disease-
modifying anti-rheumatic drugs (csDMARDs) or biologic
disease-modifying anti-rheumatic drugs (bDMARDs) with
seliciclib are not predicted. Seliciclib has a reported toxicity
profile similar to existing csDMARDs used to treat RA, and
without the myelosuppression seen with other CDK inhib-
itors.[27] Preclinical studies suggest combining CDK inhibition
with cytokine blockers has additive effects and may not increase
immune suppression.[28] Determination of the toxicity profile and
preliminary efficacy of seliciclib in combination with bDMARD
therapies within a true-to-life pharmacological context (in which
concomitant csDMARD use is permitted), will provide important
insight into its potential acceptability as an adjunctive therapy
in RA.2. Methods and analysis
2.1. Overall study design and objectives
TRAFIC is an investigator-led, multi-center, rolling phase Ib/IIa
trial investigating the safety, tolerability, and efficacy of seliciclib
as an addition to existing bDMARD therapy in patients with
moderate-severe RA. All eligible participants will receive
seliciclib, the investigational medicinal product (IMP), with no
randomization or control arm.
The primary objective of part 1 of the study (phase Ib) is to
determine the maximum tolerated dose (MTD) and safety of
seliciclib over 4weeks when given in RA as an addition to existing
bDMARD therapy. The MTD was established using a restricted
1-stage Bayesian Continual Reassessment Method (CRM)[29]
based on a target dose-limiting toxicity (DLT) probability of 35%
(similar to what is observed with methotrexate, the “anchor”
drug in RA clinical practice[30]), or determination of unacceptable
toxicity leading to cessation of the trial. It is planned that up to 7
cohorts of 3 participants each will be treated, with each cohort
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for early stopping if sufficient evidence ofMTDhas been achieved
or if the lowest IMP dose is too toxic. Part 1 of the study has been
completed and clinical data will be published in a separate
manuscript.
The primary objective of part 2 (phase IIa) is to assess the potential
efficacy, using a composite response, of seliciclib as an addition to
existing therapy following12weeksof treatment. Part 2 isdesigned
as a single arm, single stage early phase trial based on a Fleming–
A’Hern design[31] recruiting a total of 18 participants to receive the
MTD recommended from part 1 for a maximum of 12 weekly
cycles. At the conclusion of part 2, further investigation is
warranted if the observed number of clinical responses at least
equals a pre-specified critical number according to the statistical
design. As this is the first trial investigating seliciclib in this
indication as a repurposed drug and given the novel mechanism of
action, the decision to continue will also be based on pharmaco-
dynamic (PD) biomarkers and pharmacokinetic (PK) parameters,
to avoid rejecting a potentially active drug which has not achieved
pragmatic clinical measures of efficacy. A secondary aim, given
seliciclib’s potentially unique mode of action in RA, is to identify
sensitive and robust outcome measures for future RA trials of
seliciclib and similar agents in this indication.
When we wrote the initial protocol, there was a significant unmet
need for patients who had received tumor necrosis factor (TNF)
blockade but who had not reached remission. Whilst the same
was true for patients receiving other bDMARDs, more patients
were receiving anti-TNF therapy at that stage because this
treatment had been licensed for significantly longer than other
biologic agents. The initial study protocol was therefore limited
to patients receiving TNF inhibitors. However, recently more
patients are being “cycled” from a TNF inhibitor to another
bDMARD as part of their standard care and existing treatment
guidelines, thereby reducing the pool of patients suitable for
TRAFIC and significantly impacting on study recruitment. In
other words, the “unmet need” has now been shifted downstream
to include patients receiving other biologic therapies. We
therefore amended the protocol (approved June 2019) to broaden
the inclusion criteria to incorporate patients on 2 other
bDMARDs (tocilizumab and abatacept) supported by preclinical
data.[28] In addition, the 28 joint disease activity score (DAS28)
cut-off for inclusion in part 2 of the study was reduced from ≥4.0
to ≥3.2 as this was identified as a barrier to recruitment and 3.2
was felt to be a more clinically relevant cut-off.2.2. Study population
Adults (≥18 years old) fulfilling the 1987 ACR or 2010ACR/
European League Against Rheumatism (EULAR) criteria for RA
who are currently taking a bDMARD therapy for at least 3
months as part of standard clinical care and who have ongoing
moderate-severe disease activity are eligible. In part 1 of the
study, the bDMARDwas limited to anti-TNF therapy, whichwas
amended in June 2019 to include abatacept or tocilizumab. The
DAS28 cut-off in part 1 was ≥3.2. In part 2, the initial proposed
DAS28 cut-off was ≥4.0 plus clinical synovitis in at least 3 joints,
which was amended to ≥3.2 plus at least 1 joint amenable to
ultrasound-guided synovial biopsy in June 2019. The current
protocol allows anti-TNF or 2 other bDMARD therapies
(abatacept or tocilizumab) to be used either as monotherapy
or with permitted background csDMARDs (methotrexate,
sulphasalazine, and hydroxychloroquine).3Full inclusion and exclusion criteria for current protocol v11.0
(March 21, 2019) are shown in Table 1. Potential participants are
recruited from rheumatology outpatient departments in the
United Kingdom.
2.3. Ethical considerations
The studyhasbeen reviewedandgiven favourable ethical opinionby
the North East – Tyne & Wear South Research Ethics Committee
(reference number 14/NE/1075). Clinical trial authorization was
given by the Medicines and Healthcare Products Regulatory
Agency, United Kingdom. The study is being conducted in
compliance with Good Clinical Practice, the Research Governance
Framework for Health and Social Care, and national legislation
implementing the EU Clinical Trials Directive (2001/20/EC) and
subsequent amendments. Patients wishing to take part provide
written informed consent by signing and dating a trial specific
consent form, obtained prior to any study-specific procedures. The
study is registered in the ISRCTN registry (identifier 36667085).
2.4. Data collection
Data will be collected using standardized data entry and
management system. An overview of the schedule of enrolment
and timing and types of data collected in parts 1 and 2 of the
study are shown in Tables 2 and 3, respectively.
2.5. Outcome measures
2.5.1. Primary outcomemeasures. Part 1: TheMTD is defined
as the dose that is closest to the dose at which 35%of participants
experience a DLT over a 4-week treatment period with seliciclib.
A DLT is defined as the cessation of IMP due to adverse events or
reactions (AE/AR) occurring during the treatment period. AEs
and ARs are attributed (as definitely, probably, possibly,
unlikely, or unrelated) to seliciclib and other therapies and
categorised as mild, moderate or severe. These can be either
symptomatic AEs or ARs (e.g., nausea) or abnormal laboratory
parameters or investigations. DLT is based upon the patient’s
request to stop treatment, regardless of the severity classification,
or an abnormal laboratory parameter necessitating cessation of
treatment. In the event of several AEs/ARs contributing to the
decision to discontinue IMP, only a single DLT will be recorded
for the purposes of dose pathway decision making.
Part 2: Response rate at 12 weeks as a composite measure using
clinical scores (EULAR moderate response, ACR20 re-
sponse),[32,33] histological score (macrophage number in the
sublining layer of the synovium)[34–37] and magnetic resonance
imaging (MRI) score (rheumatoid arthritis MRI scoring system
(RAMRIS)).[38–40] A patient receiving seliciclib is defined as
responding if they achieve 2 out of 3 of:1. EULAR moderate response or ACR20 response
2. A reduction of sublining macrophage number of ≥20% or an
absolute mean reduction of >200macrophages/mm2 at the
end of dosing3. A reduction of RAMRIS synovitis of ≥0.5 units or osteitis
score of ≥0.2 units at the end of dosing2.6. Secondary outcome measures
Both study parts record and report:1. all AEs,
2. PD biomarkers in peripheral blood,
Pa
Table 1
Inclusion and exclusion criteria for current protocol v11.0 (March 21, 2019).
Inclusion criteria (participants must fulfil all of the following):
1. Rheumatoid arthritis fulfilling the 1987 ACR or 2010 ACR/EULAR criteria
2. Age≥18 yr
3. At least 6 mo disease duration
4. ACR Functional Class I-III
5. DAS28 ≥3.2
6. At least 1 joint amenable to ultrasound-guided synovial biopsy (For part 2 only).
7. Currently taking anti-TNF as part of standard clinical care, and have received stable treatment with a single anti-TNF agent for at least 3 mo upon entry to the study. (For
Part 1 only)
8. Currently taking anti-TNF, abatacept or tocilizumab as part of standard clinical care, and have received stable treatment with a single anti-TNF, abatacept or tocilizumab for
at least 3 mo upon entry to the study. (For Part 2 only)
9. Anti-TNF (parts 1 and 2) or other biologic therapies (abatacept or tocilizumab, part 2 only) may be administered as either monotherapy or with background conventional
DMARDs. Permitted background DMARDs are methotrexate, sulphasalazine and hydroxychloroquine, either alone or in combination, at stable dose(s) for ≥4 wk prior to
baseline visit.
10. No intramuscular glucocorticoid administration in the 4 wk period prior to baseline visit. Stable dose of non-steroidal anti-inflammatory drug (NSAID) or corticosteroid
(prednisolone7.5 mg) for ≥4 wk as part of standard clinical care are allowed.
11. Willing and able to undergo MRI scanning on 2 occasions. (For part 2 only).
12. Willing to undergo ultrasound guided synovial biopsy on 2 occasions (under local anaesthetic). (For part 2 only).
Exclusion criteria (participants must not have any of the following):
1. If patients were previously taking leflunomide a minimum period of 20 d must have elapsed between the last dose of leflunomide and the first dose of IMP.
2. Patients receiving warfarin or other anticoagulation likely to interfere with biopsy procedures. (Part 2 only).
3. Use of other IMPs within 30 d prior to trial entry (defined as date of recruitment into trial).
4. Serious or unstable co-morbidity deemed unsuitable by principal investigator for example COPD, cardiac failure, other significant autoimmune disease
5. Patients must not drink more than 2 units of alcohol per day and no more than 10 units of alcohol per week during the trial and for a 4 week period after completion of
the trial.
6. Known active infection at screening visit or at baseline (except fungal nail infection)
7. Infection requiring hospitalization or IV antibiotics within 6 wk prior to baseline
8. History of recurrent or chronic infection
9. Recent live vaccination (within 6 wk of baseline)
10. Haemoglobin <10g/dL; neutrophils< 1.5 x109/L; platelets <100x109/L
11. Patients taking ketoconazole, voriconazole, erythromycin, clarithromycin.
12. ALT or ALP>1.5x upper limit of normal
13. Estimated glomerular filtration rate <60 mL/min
14. Major surgery within 8 wk prior to baseline or planned within 3 mo from baseline.
15. Pregnancy, or women planning to become pregnant within the trial period, or women who are breast feeding
16. Females or males of child-bearing potential unwilling to use 2 forms of adequate contraception whilst taking the IMP and for one month afterwards.
Participants who fail screening as a result of minor blood test abnormalities may be re-screened and have the test(s) repeated within 7 days at the investigator’s discretion. If the tests meet the trial entry criteria on
the second occasion then the participant will be deemed to meet the entry criteria for the trial. ACR=American College of Rheumatology, ALP= alkaline phosphatase, ALT= alanine transaminase, DMARD =
disease-modifying anti-rheumatic drug, EULAR=European League Against Rheumatism, IMP= Investigational Medicinal Product, TNF = tumor necrosis factor.
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4. relationship between PD and PK markers with each other and
with AEs,
5. longitudinal changes in FACIT Fatigue Scale and
6. longitudinal changes in circulating autoantibodies.
rt 2 also records and reports:1. response rate after 1, 2, 3, 6, and 9 weeks of therapy;
2. relationship between PD and PK markers and efficacy,
3. change in synovial metabolism assessed by fluorodeoxyglu-
cose uptake by inflamed synovium measured by fluorodeox-
yglucose positron emission tomography at baseline and at
week 12 (optional);4. change from baseline in urinary metabolomic profiles during
treatment; and5. molecular changes in the synovium consistent with seliciclib
PD activity.
2.7. Investigational medicinal product
Seliciclib is the IMP. The selected dose range and schedule is
based on healthy control and oncology studies in which more4than 450 participants have received between 50 and 3600mg
seliciclib per day in a variety of intermittent dosing schedules.
Using the selected 4 days per week schedule, the longest treatment
period was 111 weeks. The terminal half-life is 3 to 4hours and
primary route of metabolism is via cytochromes 3A4 and 2B6,
the major metabolite being much less active. Tolerability in
previous studies was related to daily dose and number of
consecutive dosing days. DLTs were reversible below 1600mg of
seliciclib daily and included fatigue, nausea and vomiting,
elevated liver enzymes, and hypokalaemia. Non-limiting tox-
icities included anorexia and elevated serum creatinine.Most AEs
were mild to moderate in severity, dose-related, and generally
occurred during the first 3 weeks of therapy. Such symptoms are
familiar to RA patients, either as a manifestation of the disease
itself or as side effects of commonly prescribed csDMARDs.
Hence the experience to date, particularly lack of myelosup-
pression, suggests that seliciclib should be acceptable and well
tolerated in RA.
The IMP is supplied as a 200mg strength capsule (white opaque,
size 1). Cyclacel Pharmaceutical provides the bulk IMP. Penn
Pharmaceuticals Ltd is responsible for treatment packaging and
Table 2
Schedule for enrolment and data collection in part 1.
PART 1
Assessment/activity Visit 1 screening Visit 2 baseline Visit 3 (d 8) Visit 4 d 15 Visit 5 d 22 Visit 6 d 29
Informed consent X
Eligibility screening (including medical history) X
Physical examination X X X X X X
Laboratory tests – biochemistry, haematology X X X X X X
Pregnancy test X X X
ECG X
Drug dispensing X X X X
Collection of unused IMP X X X X
Concomitant medication X X X X X X
Adverse events X X X X X
Disease activity X X X X
Patient-reported outcomes X X X X
PK & PD bloods X X
ECG=electrocardiogram, IMP= investigational medicinal product, PD=pharmacodynamics, PK=pharmacokinetics.
Siebert et al. Medicine (2020) 99:26 www.md-journal.comlabelling. The IMP is prescribed by a trial clinician according to
the protocol and dispensed according to local pharmacy policy.
Participants return all IMP supplies in their original packaging
(even if empty) to the trial clinician or pharmacist at each visit. All
returned or unused IMP is stored in pharmacy until the end of the
trial, or until the trial manager has completed appropriate
reconciliation.
In part 1, participants receive 200, 400, 600, 800, or 1000mg
seliciclib daily for 4 consecutive days every week for 4 weeks.
Participants are assigned to the dose levels in cohorts of 3, with
400mg seliciclib assigned to the first cohort. Participants in part 1
receive IMP treatment for 4 weekly cycles (in the absence of DLT)
and, once the third subject of a cohort has attended their finalTable 3
Schedule for enrolment and data collection in part 2.
PART 2
Assessment/ activity
Visit 1
screening
Visit
2a-c
Visit 3
baseline Visit 4
Time-point (d) 42 to 0 42 to 0 1 8
Informed consent X
Eligibility screening (& medical history) X
Synovial biopsy X
MRI X
PET (optional) X
Physical examination X X X
Laboratory tests – biochemistry,
haematology
X X X
Pregnancy test X X
ECG X
Drug dispensing X X
Collection of unused IMP X
Concomitant medication X X X
Adverse events X X X
Disease activity X X X
Patient-reported outcomes X X X
PK & PD bloods X
Urine for metabolomics X X
ECG=electrocardiogram, IMP= investigational medicinal product, MRI=magnetic resonance imaging, P
5visit, the chief investigator, principal investigators from each site,
trial manager and trial statistician discuss anyAEs/ARs andDLTs
and make the decision whether or not to open the subsequent
cohort, according to the CRM algorithm, with sponsor and Data
Monitoring Committee (DMC) approval. An independent DMC
undertakes independent review with the purpose of monitoring
safety and efficacy endpoints. Dose cannot be escalated or de-
escalated by more than 200mg per cohort, and cohorts are
enrolled until the MTD was determined, the maximum sample
size reached, or if the lowest dose (200mg) is determined to be too
toxic.
In part 1 of the trial, a DLT triggers patient withdrawal and
informs the CRM algorithm. In part 2, seliciclib is withheld in theVisit 5 Visit 6 Visit 7 Visit 8 Visit 9a-b Visit 10
Telephone
follow-up
15 22 43 64 During
week 12
dosing cycle
Within 5 d
after last
IMP dose
4 wk after
last IMP
dose
X
X
X
X X X X X
X X X X X
X
X
X X X X
X X X X X
X X X X X X X
X X X X X X X
X X X X X
X X X X X
X
X X X X X X
D=pharmacodynamics, PET=positron emission tomography, PK=pharmacokinetics.
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the exception of anaemia, hypokalaemia, or other laboratory
abnormality that can bemanaged adequately by supplementation
or medications. Dosing is recommenced at the next lower dose,
and all dose reductions are permanent. In the event of a non-
severe DLT, dosing with seliciclib may be withheld until the
toxicity resolves. At this point drug is restarted at the same dose
unless the treatment delay is 2 weeks or more, in which case a
dose reduction is mandated as above.
Participants may not receive any other investigational drugs while
participating in this trial butmay receive existing standard therapies
and supportive treatment. As nausea and vomiting are commonly
reported by participants treated with seliciclib, prophylactic use of
an anti-emetic is permissible but not mandatory.2.8. Statistical considerations
All analyses are predefined and documented in the statistical
analysis plan approved by the chief investigator. The statistical
design will be reported in detail in a separate manuscript. Briefly,
part 1 will report the recommendedMTD, the Bayesian posterior
probability of DLT at each dose level (with 90% probability
interval) and the posterior probability that the DLT rate at dose
level 1 (200mg) is greater than the target level of 35%. The
number of participants experiencing DLT at each dose level,
together with the proportion of participants with DLT at that
dose level, will be reported. Secondary outcome measures
including the relationship of PD biomarkers and PK parameters
will be presented graphically.
Part 2 will assess potential efficacy of treatment based on a
composite outcome of response following 12 cycles of treatment.
Individual components of the composite response outcome and
all AEs will also be reported descriptively. Secondary outcome
measures including PK parameters and PD biomarkers will be
presented graphically.2.9. Sample size
Part 1 includes a maximum of 21 participants based on a
maximum of 7 cohorts each consisting of 3 participants. The
decision to recruit 3 participants per cohort was based on the
proposed 35%DLT rate. The performance of the Bayesian design
based on 21 participants was assessed via simulations under
several clinically relevant scenarios in terms of accuracy of
selecting the true MTD, optimal allocation, and average
percentage of participants being treated at a dose higher than
the MTD.
Part 2 is based on a Fleming–A’Hern design[32] and assumes a
composite response rate to reject seliciclib (p0) <25% and a
response rate to investigate seliciclib further (p1) >50%. The
justification to investigate seliciclib further is based on observing
a minimum critical number of responses. As an early phase trial,
the error levels have been inflated but restricted to an acceptable
level of 15% alpha (type 1) and 20% beta (type 2). With these
stated parameters the target recruitment for part 2a is calculated
as 18 participants.
As this is the first trial investigating seliciclib as a repurposed
drug for RA and, given the novel mechanism of action, the
decision to continue will also be based on PD biomarkers and
PK parameters to minimise the risk of rejecting a potentially
active drug which has not achieved pragmatic clinical measures
of efficacy. In terms of synovial PD biomarkers, the decision to6continue will be informed by the following observations and
evidence:1. Polymerase chain reaction of synovial tissue for genes of
interest relevant to fibroblast biology, inflammation, cell cycle,
and apoptosis, applied to mRNA extracted from synovial
tissue;2. PD effects of seliciclib on the synovial fibroblast using
immunohistochemistry and appropriate dual staining with
fibroblast markers, including reagents that recognise phospho-
specific isoforms of RNA polymerase II and the retinoblasto-
ma protein, which are targets of CDK7/9 and CDK2,
respectively.3. Markers of cell proliferation, such as Ki-67, within the
synovial fibroblast population.
If any of these criteria suggest a positive PD effect of seliciclib in
the synovium, particularly if the IMP is well tolerated, then a
decision may be taken to progress to a further study with a more
focussed dose range and using outcomemeasures informed by the
current study.2.10. Trial monitoring
The trial is monitored by an independent DMC consisting of 2
physicians not connected to the trial, 1 acting as chair, and 1
statistician. The purpose of this committee is to undertake
independent review and monitor efficacy and safety endpoints.
The committee convened prior to the start of recruitment to
discuss the dose transition pathway as recommended by the
proposed CRM. The DMC members are updated after
completion of each cohort in part 1. The DMC also convenes
at the end of part 1, during recruitment of part 2 and at trial
completion, with additional interim meetings at the request of the
DMC members in light of emerging safety data.
A Trial Steering Committee (TSC) provides overall supervision of
the trial. The TSC consists of an independent chairperson, an
independent clinician plus principal investigators, a Cyclacel
representative and lay representation. In addition, representatives
from the Trial Management Group, sponsor and funder will be
invited. Requests for data sharing will be reviewed and
considered by the TSC in conjunction with the chief investigator
and sponsor.
The trial may be subject to inspection and audit by TheNewcastle
upon Tyne Hospitals NHS Foundation Trust under their remit as
Sponsor, and other regulatory bodies to ensure adherence to
GCP.2.11. Patient and public involvement
Two patient research partners have been involved throughout
this project. They have contributed to the initial project design
and protocol, reviewed and improved the information sheet for
participants, and have taken part in regular project steering group
meetings. The patient research partners will review the results of
this study, contribute to the drafting of lay summaries for all
manuscripts and will advise and participate in the dissemination
of results to lay audiences.2.12. Study discontinuation
The trial may be prematurely discontinued on the basis of new
safety information, or for other reasons given by the DMC and/or
Siebert et al. Medicine (2020) 99:26 www.md-journal.comTSC, sponsor, regulatory authority, or Ethics Committee
concerned. There are 2 early stopping rules included in part 1
to allow for early termination if:1. there is a high probability that the posterior probability of
DLT at the lowest dose is greater than the target DLT rate,
indicating that the lowest dose is too toxic or2. sufficient patients have already been allocated at the current
MTD, which would also be the recommended dose level for
the next cohort if the trial continues.
3. Discussion
The TRAFIC study aims to repurpose seliciclib to address an area
of unmet need in RA. This is the first study of a CDK inhibitor or
other therapeutic agent targeting the synovial fibroblast in RA,
and employs efficient trial designs that additionally avoid the
requirement for control arms in part 1 or part 2 of the study.
While seliciclib has been tested in patients with malignancy,[27,41]
theMTD for RA cannot be assumed to be the same. Patients with
RA will have received a number of immunomodulating DMARD
therapies, anti-inflammatories and analgesics as part of their
previous treatment. Furthermore, patients with RAmay exhibit a
different tolerance to adverse effects than patients with cancer.
The MTD dose for seliciclib in patients with RA therefore has to
be established in part 1 of this study before assessment of efficacy
can be undertaken.
The potential target RA patient population for seliciclib was
extensively discussed. There are multiple csDMARD and
bDMARD therapies, with established efficacy and safety,
available for the treatment of early and moderate-severe active
RA. In general, patients who fail to respond to initial csDMARDs
are rapidly escalated to biologic therapies. Despite the distinct
mechanisms of action of bDMARDs, their efficacy is surprisingly
similar in RA clinical trials, including a therapeutic “ceiling” such
that only 10% to 20% of patients achieve remission. The
hypothesis under test in TRAFIC is that these unexpected
phenomena could be explained if a proportion of RA disease
activity were attributable to the synovial fibroblast. This cell is an
integral element of RA “pannus”, the tissue that erodes bone and
cartilage; it also secretes pro-inflammatory cytokines and
chemokines, thereby potentially sustaining inflammation in the
presence of potent biologic therapies. Current RA therapies do
not target synovial fibroblasts, hence the rationale for adding
seliciclib to existing therapeutic regimes in patients with a partial
response to biologic therapies. The DAS28 cut-offs for inclusion
in this study was chosen to reflect ongoing disease activity and for
being feasible for recruitment. Part 1 was designed to determine
the MTD of seliciclib, and a DAS28 score of ≥3.2 was chosen. In
part 2, a higher DAS28 score of ≥4.0 was initially selected to
maximise efficacy assessment but subsequently this was reduced
to ≥3.2 to improve recruitment. DAS28 scores of ≥3.2 indicate
moderate disease activity, with DAS28 <3.2 representing low
disease activity[42] and DAS28 <2.6 representing remission.[43]
Part 1 utilised a Bayesian model-based CRM dose finding design
used more frequently in oncology. CRM designs have been
shown to be more efficient than the often used rule-based designs,
such as the 3+3; CRM designs require fewer patients on average
and treat more patients at potentially therapeutic doses at or near
to the MTD.[44] In contrast to rule-based designs, CRM designs
utilise all available accumulating data to inform decisions
regarding dosing for successive patients. Part 2 is designed as7a proof of concept trial with a go/no-go decision for a further
randomized phase II/III trial. This single arm, single stage, early-
phase trial uses the Fleming–A’Hern design which incorporates
specification of a desired level of response and a level of response
below which the treatment would be considered ineffective.
The part 2 outcomes were chosen to reflect both symptoms and
biomarkers. The latter are particularly important for a study
design that does not include a placebo or control group. ACR
responses are composite scores reflecting swollen and tender
joints, an acute phase biomarker, physician, and patient global
assessments, an assessment of function (Health Assessment
Questionnaire) and an assessment of pain. ACR20 was initially
developed to reflect an improvement in phase II/III clinical trials
that was unlikely to represent a placebo response. Similarly, a
moderate EULAR response is likely to reflect a true benefit.
Nonetheless, in a single arm study where all patients receive
active treatment, a strong placebo response is anticipated. Hence
the inclusion of validated biomarkers based on a reduction of
macrophages in the synovial sublining and MRI evidence of
improvement in synovitis and/or osteitis. In previous studies,
prednisolone and a CCR1 antagonist resulted in 40% to 50%
reduction in sublining macrophages over 12 to 14 weeks in
controlled studies, while in contrast patients receiving placebo or
stable background therapy demonstrated a 10% to 25% increase
in sublining macrophages.[34,36] The RAMRIS criteria for MRI
improvement reflect those observed in a 12 week phase II study of
fostamatinib (Syk kinase inhibitor) in RA, albeit a much larger
study than the current one.[40] The RAMRIS score in the placebo
group of that study increased (indicating disease progression).
We believe that fluorodeoxyglucose positron emission tomogra-
phy, reflecting synovial metabolism, could also provide a useful
outcomemeasure predicted to reduce after seliciclib. However, as
a non-validated outcome measure this is optional for part 2
participants and not included in the Fleming–A’Hern decision
process.
TRAFIC is the first trial to use a cell cycle inhibitor to target the
synovial fibroblast in patients with RA. It is also innovative in
employing CRM to identify the MTD in part 1, and a single arm
Fleming–A’Hern design to seek evidence of efficacy in part 2.
Both are efficient trial designs that should expedite further
development if evidence of safety and efficacy emerges. Lessons
learned from the recruitment challenges in this study will also
inform study design of subsequent studies arising from this line of
work, and similar studies in RA.3.1. Trial status
Part 1 of the study is completed and part 2 is ongoing using the
MTD of seliciclib identified in part 1. Recruitment for part 2 has
been slow, necessitating amendments to the background
bDMARD (abatacept and tocilizumab also allowed) and
DAS28 cut-off inclusion criteria as outlined.Acknowledgments
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